🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion

    Lacuna Pharma Pty Ltd

    Paroxysmal Nocturnal Hemoglobinuria

    phase 2 small molecule active

    1 trial

  2. AST-OPC1

    Lineage Cell Therapeutics

    Cervical Spinal Cord Injury

    phase 2 mab completed

    1 trial

  3. ASTX727

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or solid tumors

    phase 2 small molecule active

    1 trial

  4. AT-1501

    Eledon Pharmaceuticals

    Kidney Transplant Rejection

    phase 2 small molecule active

    2 trials

  5. AT-1501

    Eledon Pharmaceuticals

    Prevention of Rejection in Kidney Transplant

    phase 2 small molecule active

    1 trial

  6. AUTO1, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludara 50 mg powder for solution for injection or infusion

    Autolus GmbH

    Systemic Lupus Erythematosus with Active Lupus Nephritis

    phase 2 small molecule active

    1 trial

  7. AUY922

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastrointestinal Stromal Tumor

    phase 2 small molecule active

    1 trial

  8. AZACITIDINE

    ALX ONCOLOGY HOLDINGS INC

    Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease

    phase 2 small molecule active

    1 trial

  9. AZD2962, AZD2962

    AstraZeneca AB

    Myelodysplastic syndromes, Dysplastic chronic myelomonocytic leukaemia

    phase 2 small molecule active

    1 trial

  10. AZD3632, AZD3632

    AstraZeneca AB

    Relapsed or refractory acute leukaemia or Myelodysplastic Syndromes with HOX overexpression genotypes

    phase 2 small molecule active

    1 trial

  11. AZD8630, AZD8630, AZD8630 Placebo, AZD8630

    AstraZeneca AB

    Asthma in adults who remain uncontrolled despite medium to high dose ICS plus LABA, and who are at risk of exacerbations.

    phase 2 small molecule active

    1 trial

  12. AZD9291

    Hospital Authority, Hong Kong

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  13. Abatacept s.c.

    The First People's Hospital of Lianyungang

    Abatacept

    phase 2 small molecule active

    1 trial

  14. Abemaciclib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Metastases From Colorectal Cancer (mCRC)

    phase 2 small molecule active

    1 trial

  15. Abiraterone Acetate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  16. Abraxane 5 mg/ml powder for dispersion for infusion., CISPLATIN, VALPROIC ACID, SIMVASTATIN, CAPECITABINE, VALPROIC ACID, GEMCITABINE

    Fondazione Telethon ETS

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 2 small molecule active

    1 trial

  17. Abraxane 5 mg/ml powder for dispersion for infusion., Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, RoActemra 20 mg/mL concentrate for solution for infusion, Gemcitabin AqVida 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Gemcitabin Kabi 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Avastin 25 mg/ml concentrate for solution for infusion., ATEZOLIZUMAB, Tiragolumab

    Hoffmann-La Roche

    Pancreatic ductal adenocarcinoma (PDAC)

    phase 2 small molecule active

    1 trial

  18. Abraxane 5 mg/ml powder for dispersion for infusion., IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, LEVOFOLINATE DE CALCIUM ZENTIVA 25 mg/2,5ml, solution injectable (IM/IV)

    The George Institute

    local advenced pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  19. Abraxane 5 mg/ml powder for dispersion for infusion., PEMETREXED , GEN1042 DP, CARBOPLATIN , FLUOROURACIL , PACLITAXEL , PEMBROLIZUMAB, GEMCITABINE , CISPLATIN

    Genmab A/S

    Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).

    phase 2 small molecule active

    1 trial

  20. Absorbable and moldable skull base support plate

    The First People's Hospital of Lianyungang

    Sellar Tumor

    phase 2 other active

    1 trial

  21. Acasunlimab, Abraxane 5 mg/ml powder for dispersion for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 100 mg powder for concentrate for solution for infusion., Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, Pazenir 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion.

    Genmab A/S

    Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.

    phase 2 small molecule active

    1 trial

  22. Acetohydroxamic Acid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multidrug-Resistant Tuberculosis

    phase 2 small molecule active

    1 trial

  23. Active tDCS + task oriented practice

    United Therapeutics Europe Ltd

    Cervical Spinal Cord Injruy

    phase 2 other completed

    1 trial

  24. Actrapid 100 international units/ml solution for injection in vial, Natriumklorid Fresenius Kabi, 9 mg/ml, infusionsvätska, lösning, SODIUM CHLORIDE, Natriumklorid Fresenius Kabi 9 mg/ml, spädningsvätska för parenteral användning, Albumin Baxalta 200 g/l infusionsvätska, lösning, Glucos Fresenius Kabi 200 mg/ml infusionsvätska, lösning, A24110He

    Lacuna Pharma Pty Ltd

    Moderate to severe hypertriglyceridemia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources